{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:50Z","timestamp":1793303570237,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genetic diversity of germline variants in breast cancer (BC) predisposition genes is unexplored in miscegenated populations, such those living in Latin America. We evaluated 1663 Brazilian BC patients, who underwent hereditary multigene panel testing (20\u201338 cancer susceptibility genes), to determine the spectrum and prevalence\u00a0of pathogenic\/likely pathogenic (P\/LP) variants and variants of uncertain significance (VUS). Associations between P\/LP variants and BC risk were estimated in a case\u2013control analysis of BC patients and 18,919 Brazilian reference controls (RC). In total, 335 (20.1%) participants carried germline P\/LP variants: 167 (10.0%) in<jats:italic>BRCA1\/2<\/jats:italic>, 122 (7.3%) in BC actionable non-BRCA genes and 47 (2.8%) in candidate genes or other cancer predisposition genes. Overall, 354 distinctive P\/LP variants were identified in 23 genes. The most commonly mutated genes were:<jats:italic>BRCA1<\/jats:italic>(27.4%),<jats:italic>BRCA2<\/jats:italic>(20.3%),<jats:italic>TP53<\/jats:italic>(10.5%), monoallelic<jats:italic>MUTYH<\/jats:italic>(9.9%),<jats:italic>ATM<\/jats:italic>(8.8%),<jats:italic>CHEK2<\/jats:italic>(6.2%) and<jats:italic>PALB2<\/jats:italic>(5.1%). The Brazilian variant<jats:italic>TP53<\/jats:italic>R337H (c.1010G&gt;A, p.Arg337His), detected in 1.6% of BC patients and 0.1% of RC, was strongly associated with risk of BC,\u00a0OR\u00a0= 17.4 (95% CI: 9.4\u201332.1; p\u2009&lt;\u20090.0001); monoallelic<jats:italic>MUTYH<\/jats:italic>variants\u00a0c.1187G&gt;A and\u00a0c.536A&gt;G, detected in 1.2% (0.9% RC) and 0.8% (0.4% RC) of the patients, respectively, were not associated with the odds of BC, the former with OR\u00a0= 1.4 (95% CI: 0.8\u20132.4; p\u2009=\u20090.29) and the latter with OR\u00a0= 1.9 (95% CI: 0.9\u20133.9; p\u2009=\u20090.09). The overall VUS rate was 46.1% for the entire patient population. Concluding, the use of multigene panel testing almost doubled the identification of germline P\/LP variants in clinically actionable predisposition genes in BC patients. In Brazil, special attention should be given to<jats:italic>TP53<\/jats:italic>P\/LP variants.<\/jats:p>","DOI":"10.1038\/s41598-022-07383-1","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T15:02:25Z","timestamp":1646838145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Detection of germline variants in Brazilian breast cancer patients using multigene panel testing"],"prefix":"10.1038","volume":"12","author":[{"given":"Rodrigo Santa Cruz","family":"Guindalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Vilela","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Fumio Whitaker","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius Marques","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana Ver\u00f3nica Mendoza","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rika","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola Paoli Mendes","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Aparecida Azevedo Koike","family":"Folgueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"7383_CR1","unstructured":"Minist\u00e9rio da Sa\u00fade. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Estimativa 2020: Incid\u00eancia de c\u00e2ncer no Brasil. https:\/\/www.inca.gov.br\/sites\/ufu.sti.inca.local\/files\/\/media\/document\/\/estimativa-2020-incidencia-de-cancer-no-brasil.pdf (2019)."},{"key":"7383_CR2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39, 593\u2013620 (2018).","journal-title":"Hum. Mutat."},{"key":"7383_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","volume":"1","author":"AW Kurian","year":"2017","unstructured":"Kurian, A. W. et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precis. Oncol. 1, 1\u201312 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"7383_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen, F. C., van Overeem Hansen, T. & S\u00f8rensen, C. S. Hereditary breast and ovarian cancer: New genes in confined pathways. Nat. Rev. Cancer. 16, 599\u2013612 (2016).","journal-title":"Nat. Rev. Cancer."},{"key":"7383_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","volume":"45","author":"K Michailidou","year":"2013","unstructured":"Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353\u2013361 (2013).","journal-title":"Nat. Genet."},{"key":"7383_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fgene.2018.00280","volume":"9","author":"M Rivandi","year":"2018","unstructured":"Rivandi, M., Martens, J. W. M. & Hollestelle, A. Elucidating the underlying functional mechanisms of breast cancer susceptibility through post-GWAS analyses. Front. Genet. 9, 280. https:\/\/doi.org\/10.3389\/fgene.2018.00280 (2018).","journal-title":"Front. Genet."},{"key":"7383_CR7","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton, D. F. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372, 2243\u20132257 (2015).","journal-title":"N. Engl. J. Med."},{"key":"7383_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/1678-4685-gmb-2018-0076","volume":"42","author":"AM de Souza","year":"2019","unstructured":"de Souza, A. M., Resende, S. S., de Sousa, T. N. & de Brito, C. F. A. A systematic scoping review of the genetic ancestry of the Brazilian population. Genet. Mol. Biol. 42, 495\u2013508 (2019).","journal-title":"Genet. Mol. Biol."},{"key":"7383_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2007.10.044","volume":"261","author":"EI Palmero","year":"2008","unstructured":"Palmero, E. I. et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 261, 21\u201325 (2008).","journal-title":"Cancer Lett."},{"key":"7383_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jamaoncol.2015.28","volume":"1","author":"AW Kurian","year":"2015","unstructured":"Kurian, A. W. & Ford, J. M. Multigene panel testing in oncology practice: How should we respond?. JAMA Oncol. 1, 277\u2013278 (2015).","journal-title":"JAMA Oncol."},{"key":"7383_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cge.12524","volume":"88","author":"C Cybulski","year":"2015","unstructured":"Cybulski, C. et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin. Genet. 88, 366\u2013370 (2015).","journal-title":"Clin. Genet."},{"key":"7383_CR12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond, A. et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 1, 943\u2013951 (2015).","journal-title":"JAMA Oncol."},{"key":"7383_CR13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian, A. W. et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32, 2001\u20132009 (2014).","journal-title":"J. Clin. Oncol."},{"key":"7383_CR14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","volume":"16","author":"H Laduca","year":"2014","unstructured":"Laduca, H. et al. Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients. Genet. Med. 16, 830\u2013837 (2014).","journal-title":"Genet. Med."},{"key":"7383_CR15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gim.2014.176","volume":"17","author":"KN Maxwell","year":"2015","unstructured":"Maxwell, K. N. et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1\/2-negative patients with early-onset breast cancer. Genet. Med. 17, 630\u2013638 (2015).","journal-title":"Genet. Med."},{"key":"7383_CR16","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","volume":"34","author":"ER Thompson","year":"2016","unstructured":"Thompson, E. R. et al. Panel testing for familial breast cancer: Calibrating the tension between research and clinical care. J. Clin. Oncol. 34, 1455\u20131459 (2016).","journal-title":"J. Clin. Oncol."},{"key":"7383_CR17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung, N. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121, 25\u201333 (2015).","journal-title":"Cancer"},{"key":"7383_CR18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung, N. et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J. Clin. Oncol. 34, 1460\u20131468 (2016).","journal-title":"J. Clin. Oncol."},{"key":"7383_CR19","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. (2020)."},{"key":"7383_CR20","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","volume":"31","author":"G Cust\u00f3dio","year":"2013","unstructured":"Cust\u00f3dio, G. et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J. Clin. Oncol. 31, 2619\u20132626 (2013).","journal-title":"J. Clin. Oncol."},{"key":"7383_CR21","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","volume":"22","author":"J Balma\u00f1a","year":"2011","unstructured":"Balma\u00f1a, J., D\u00edez, O., Rubio, I. T. & Cardoso, F. BRCA in breast cancer: ESMO clinical practice guidelines. Ann. Oncol. 22, vi31\u2013vi41 (2011).","journal-title":"Ann. Oncol."},{"key":"7383_CR22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-006-9378-6","volume":"103","author":"MCB Gomes","year":"2007","unstructured":"Gomes, M. C. B. et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res. Treat. 103, 349\u2013353 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"7383_CR23","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.18632\/oncotarget.25123","volume":"9","author":"G Encinas","year":"2018","unstructured":"Encinas, G. et al. Somatic mutations in early onset luminal breast cancer. Oncotarget 9, 22460\u201322479 (2018).","journal-title":"Oncotarget"},{"key":"7383_CR24","doi-asserted-by":"publisher","first-page":"e57581","DOI":"10.1371\/journal.pone.0057581","volume":"8","author":"DM Carraro","year":"2013","unstructured":"Carraro, D. M. et al. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: A portrait of early-onset breast cancer in Brazil. PLoS ONE 8, e57581. https:\/\/doi.org\/10.1371\/journal.pone.0057581 (2013).","journal-title":"PLoS ONE"},{"key":"7383_CR25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1590\/S1415-47572004000400006","volume":"27","author":"JJ Louren\u00e7o","year":"2004","unstructured":"Louren\u00e7o, J. J. et al. BRCA1 mutations in Brazilian patients. Genet. Mol. Biol. 27, 500\u2013504 (2004).","journal-title":"Genet. Mol. Biol."},{"key":"7383_CR26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/S1516-31802005000400007","volume":"123","author":"RM Dufloth","year":"2005","unstructured":"Dufloth, R. M. et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med. J. 123, 192\u2013197 (2005).","journal-title":"Sao Paulo Med. J."},{"key":"7383_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-15-55","volume":"15","author":"FC Silva","year":"2014","unstructured":"Silva, F. C. et al. Hereditary breast and ovarian cancer: Assessment of point mutations and copy number variations in Brazilian patients. BMC Med. Genet. 15, 1\u201311 (2014).","journal-title":"BMC Med. Genet."},{"key":"7383_CR28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1590\/S0100-879X2009000500009","volume":"42","author":"VF Esteves","year":"2009","unstructured":"Esteves, V. F. et al. The Brazilian Network of Breast and Ovarian Familial Cancer Aggregation. Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. Braz. J. Med. Biol. Res. 42, 453\u2013457 (2009).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"7383_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1897-4287-9-12","volume":"9","author":"IP Ewald","year":"2011","unstructured":"Ewald, I. P. et al. Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered. Cancer Clin. Pract. 9, 1\u20138 (2011).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"7383_CR30","doi-asserted-by":"publisher","first-page":"14012","DOI":"10.1038\/hgv.2014.12","volume":"1","author":"GES Felix","year":"2014","unstructured":"Felix, G. E. S. et al. Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: Characterizing a Northeast Brazilian Population. Hum. Genome Var. 1, 14012. https:\/\/doi.org\/10.1038\/hgv.2014.12 (2014).","journal-title":"Hum. Genome Var."},{"key":"7383_CR31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/1678-4685-gmb-2014-0363","volume":"39","author":"EI Palmero","year":"2016","unstructured":"Palmero, E. I. et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet. Mol. Biol. 39, 210\u2013222 (2016).","journal-title":"Genet. Mol. Biol."},{"key":"7383_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0187630","volume":"12","author":"B Alemar","year":"2017","unstructured":"Alemar, B. et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?. PLoS ONE 12, 1\u201318 (2017).","journal-title":"PLoS ONE"},{"key":"7383_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-27315-2","volume":"8","author":"EI Palmero","year":"2018","unstructured":"Palmero, E. I. et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci. Rep. 8, 1\u201310 (2018).","journal-title":"Sci. Rep."},{"key":"7383_CR34","doi-asserted-by":"crossref","first-page":"80465","DOI":"10.18632\/oncotarget.12610","volume":"7","author":"GC Fernandes","year":"2016","unstructured":"Fernandes, G. C. et al. Prevalence of BRCA1\/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 7, 80465\u201380481 (2016).","journal-title":"Oncotarget"},{"key":"7383_CR35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-015-3629-3","volume":"154","author":"J Dutil","year":"2015","unstructured":"Dutil, J. et al. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: A clinical perspective. Breast Cancer Res. Treat. 154, 441\u2013453 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"7383_CR36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/humu.23673","volume":"40","author":"KC de Andrade","year":"2018","unstructured":"de Andrade, K. C. et al. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis. Hum. Mutat. 40, 97\u2013105 (2018).","journal-title":"Hum. Mutat."},{"key":"7383_CR37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S1470-2045(09)70089-0","volume":"10","author":"MIW Achatz","year":"2009","unstructured":"Achatz, M. I. W., Hainaut, P. & Ashton-Prolla, P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: A case for newborn screening?. Lancet Oncol. 10, 920\u2013925 (2009).","journal-title":"Lancet Oncol."},{"key":"7383_CR38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12282-018-00938-z","volume":"26","author":"NM Cipriano Jr","year":"2019","unstructured":"Cipriano, N. M. Jr. et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer 26, 397\u2013405 (2019).","journal-title":"Breast Cancer"},{"key":"7383_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12920-019-0652-y","volume":"13","author":"E da Costa","year":"2020","unstructured":"da Costa, E. et al. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: Analysis of a 21 gene panel in the Brazilian population. BMC Med. Genom. 13, 21. https:\/\/doi.org\/10.1186\/s12920-019-0652-y (2020).","journal-title":"BMC Med. Genom."},{"key":"7383_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-8-357","volume":"8","author":"JG Assump\u00e7\u00e3o","year":"2008","unstructured":"Assump\u00e7\u00e3o, J. G. et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8, 1\u20136 (2008).","journal-title":"BMC Cancer"},{"key":"7383_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1897-4287-10-3","volume":"10","author":"MCB Gomes","year":"2012","unstructured":"Gomes, M. C. B. et al. The R337H mutation in TP53 and breast cancer in Brazil. Hered. Cancer Clin. Pract. 10, 3. https:\/\/doi.org\/10.1186\/1897-4287-10-3 (2012).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"7383_CR42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JGO.19.00170","volume":"6","author":"MI Achatz","year":"2020","unstructured":"Achatz, M. I. et al. Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil. JCO Glob. Oncol. 6, 439\u2013452 (2020).","journal-title":"JCO Glob. Oncol."},{"key":"7383_CR43","doi-asserted-by":"publisher","first-page":"eaba3231","DOI":"10.1126\/sciadv.aba3231","volume":"6","author":"EM Pinto","year":"2020","unstructured":"Pinto, E. M. et al. XAF1 as a modifier of p53 function and cancer susceptibility. Sci. Adv. 6, eaba3231. https:\/\/doi.org\/10.1126\/sciadv.aba3231 (2020).","journal-title":"Sci. Adv."},{"key":"7383_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1897-4287-12-1","volume":"12","author":"NM Cury","year":"2014","unstructured":"Cury, N. M., Ferraz, V. E. F. & Silva, W. A. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families. Hered. Cancer Clin. Pract. 12, 1\u20138 (2014).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"7383_CR45","doi-asserted-by":"publisher","first-page":"e99893","DOI":"10.1371\/journal.pone.0099893","volume":"9","author":"J Giacomazzi","year":"2014","unstructured":"Giacomazzi, J. et al. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil. PLoS ONE 9, e99893. https:\/\/doi.org\/10.1371\/journal.pone.0099893 (2014).","journal-title":"PLoS ONE"},{"key":"7383_CR46","doi-asserted-by":"publisher","first-page":"e0247363","DOI":"10.1371\/journal.pone.0247363","volume":"16","author":"RL Sandoval","year":"2021","unstructured":"Sandoval, R. L. et al. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. PLoS ONE 16, e0247363. https:\/\/doi.org\/10.1371\/journal.pone.0247363 (2021).","journal-title":"PLoS ONE"},{"key":"7383_CR47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","unstructured":"Breast Cancer Association Consortium. Breast cancer risk genes: Association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428\u2013439 (2021).","journal-title":"N. Engl. J. Med."},{"key":"7383_CR48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10549-020-05985-9","volume":"185","author":"R Gomes","year":"2021","unstructured":"Gomes, R. et al. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1\/2-negative Brazilian patients. Breast Cancer Res. Treat. 185, 851\u2013861 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"7383_CR49","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/jpm11060548","volume":"11","author":"M Fonfria","year":"2021","unstructured":"Fonfria, M. et al. Prevalence and clinicopathological characteristics of moderate and high-penetrance genes in non-BRCA1\/2 breast cancer high-risk Spanish families. J. Pers. Med. 11, 548. https:\/\/doi.org\/10.3390\/jpm11060548 (2021).","journal-title":"J. Pers. Med."},{"key":"7383_CR50","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz, C. P. et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin. Cancer Res. 23, e38\u2013e45. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0408 (2017).","journal-title":"Clin. Cancer Res."},{"key":"7383_CR51","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/bcr2810","volume":"13","author":"F Le Calvez-Kelm","year":"2011","unstructured":"Le Calvez-Kelm, F. et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: Results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res. 13, R6. https:\/\/doi.org\/10.1186\/bcr2810 (2011).","journal-title":"Breast Cancer Res."},{"key":"7383_CR52","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","volume":"53","author":"MC Southey","year":"2016","unstructured":"Southey, M. C. et al. PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. J. Med. Genet 53, 800\u2013811 (2016).","journal-title":"J. Med. Genet"},{"key":"7383_CR53","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.3390\/cancers12113254","volume":"12","author":"A Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o, A. et al. The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor. Cancers 12, 3254. https:\/\/doi.org\/10.3390\/cancers12113254 (2020).","journal-title":"Cancers"},{"key":"7383_CR54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/genes11080856","volume":"11","author":"WM Alenezi","year":"2020","unstructured":"Alenezi, W. M., Fierheller, C. T., Recio, N. & Tonin, P. N. Literature review of BARD1 as a cancer predisposing gene with a focus on breast and ovarian cancers. Genes 11, 856. https:\/\/doi.org\/10.3390\/genes11080856 (2020).","journal-title":"Genes"},{"key":"7383_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/genes12020150","volume":"12","author":"P Rofes","year":"2021","unstructured":"Rofes, P. et al. BARD1 pathogenic variants are associated with triple-negative breast cancer in a Spanish hereditary breast and ovarian cancer cohort. Genes 12, 150. https:\/\/doi.org\/10.3390\/genes12020150 (2021).","journal-title":"Genes"},{"key":"7383_CR56","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/j.gastro.2014.01.022","volume":"146","author":"AK Win","year":"2014","unstructured":"Win, A. K. et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146, 1208\u20131211 (2014).","journal-title":"Gastroenterology"},{"key":"7383_CR57","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Breast Cancer 1.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (2021)."},{"key":"7383_CR58","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian, A. W. et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 4, 1066\u20131072 (2018).","journal-title":"JAMA Oncol."},{"key":"7383_CR59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41436-020-00957-2","volume":"23","author":"C Mighton","year":"2021","unstructured":"Mighton, C., Shickh, S., Uleryk, E., Pechlivanoglou, P. & Bombard, Y. Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: A systematic review and meta-analysis. Genet. Med. 23, 22\u201333 (2021).","journal-title":"Genet. Med."},{"key":"7383_CR60","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10549-018-4938-0","volume":"172","author":"AR de Souza Timoteo","year":"2018","unstructured":"de Souza Timoteo, A. R. et al. A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer. Breast Cancer Res. 172, 637\u2013646 (2018).","journal-title":"Breast Cancer Res."},{"key":"7383_CR61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12282-020-01165-1","volume":"28","author":"G Bandeira","year":"2021","unstructured":"Bandeira, G. et al. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer. Breast Cancer 28, 346\u2013354 (2021).","journal-title":"Breast Cancer"},{"key":"7383_CR62","doi-asserted-by":"publisher","first-page":"e2837","DOI":"10.6061\/clinics\/2021\/e2837","volume":"76","author":"TR Nagy","year":"2021","unstructured":"Nagy, T. R. et al. Germline and Somatic mutations in postmenopausal breast cancer patients. Clinics 76, e2837. https:\/\/doi.org\/10.6061\/clinics\/2021\/e2837 (2021).","journal-title":"Clinics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07383-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:05:42Z","timestamp":1726790742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07383-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7383"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07383-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Founders and employees of Mendelics An\u00e1lise Gen\u00f4mica served as coinvestigators in this study and provided material support, including germline testing and interpretation, as described in the manuscript. The specific coinvestigators listed as authors participated in the review and final approval of the submitted manuscript.\u00a0R.S.C.G. acted as a consultant for AstraZeneca, GlaxoSmithKline and Igenomix; received speaker honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck\u00a0Sharpe & Dohme Brasil, Novartis, and Roche outside the submitted work; and has equity in Mendelics An\u00e1lise Gen\u00f4mica. J.P.F.W.K., A.V., D.S. and F.K. are co-founders at Mendelics An\u00e1lise Gen\u00f4mica. O.I.O. is co-founder at CancerIQ;\u00a0serves as scientific advisor at Tempus;\u00a0and is on the advisory board of 54gene. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4190"}}